JPWO2020210507A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020210507A5 JPWO2020210507A5 JP2021559793A JP2021559793A JPWO2020210507A5 JP WO2020210507 A5 JPWO2020210507 A5 JP WO2020210507A5 JP 2021559793 A JP2021559793 A JP 2021559793A JP 2021559793 A JP2021559793 A JP 2021559793A JP WO2020210507 A5 JPWO2020210507 A5 JP WO2020210507A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cell line
- sirna
- nucleotide sequence
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024094278A JP7706607B2 (ja) | 2019-04-12 | 2024-06-11 | 操作された産生細胞株ならびにそれを作製および使用する方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962833548P | 2019-04-12 | 2019-04-12 | |
| US62/833,548 | 2019-04-12 | ||
| US201962839207P | 2019-04-26 | 2019-04-26 | |
| US62/839,207 | 2019-04-26 | ||
| US202062979483P | 2020-02-21 | 2020-02-21 | |
| US62/979,483 | 2020-02-21 | ||
| PCT/US2020/027489 WO2020210507A1 (en) | 2019-04-12 | 2020-04-09 | Engineered producer cell lines and methods of making and using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094278A Division JP7706607B2 (ja) | 2019-04-12 | 2024-06-11 | 操作された産生細胞株ならびにそれを作製および使用する方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022526646A JP2022526646A (ja) | 2022-05-25 |
| JPWO2020210507A5 true JPWO2020210507A5 (https=) | 2023-04-17 |
| JP2022526646A5 JP2022526646A5 (https=) | 2023-04-17 |
| JP7560475B2 JP7560475B2 (ja) | 2024-10-02 |
Family
ID=70465550
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559793A Active JP7560475B2 (ja) | 2019-04-12 | 2020-04-09 | 操作された産生細胞株ならびにそれを作製および使用する方法 |
| JP2024094278A Active JP7706607B2 (ja) | 2019-04-12 | 2024-06-11 | 操作された産生細胞株ならびにそれを作製および使用する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024094278A Active JP7706607B2 (ja) | 2019-04-12 | 2024-06-11 | 操作された産生細胞株ならびにそれを作製および使用する方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US12018288B2 (https=) |
| EP (2) | EP4603579A3 (https=) |
| JP (2) | JP7560475B2 (https=) |
| KR (1) | KR20210152514A (https=) |
| CN (1) | CN113966395B (https=) |
| AU (1) | AU2020270960B2 (https=) |
| BR (1) | BR112021020391A2 (https=) |
| CA (1) | CA3136246A1 (https=) |
| CO (1) | CO2021013699A2 (https=) |
| IL (1) | IL287106A (https=) |
| MX (1) | MX2021012489A (https=) |
| PH (1) | PH12021552577A1 (https=) |
| SG (1) | SG11202110904PA (https=) |
| TW (1) | TWI859216B (https=) |
| WO (1) | WO2020210507A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4189077A1 (en) | 2020-07-30 | 2023-06-07 | Shape Therapeutics Inc. | Stable cell lines for inducible production of raav virions |
| WO2023019168A1 (en) | 2021-08-11 | 2023-02-16 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating a muscular dystrophy |
| AU2022373653A1 (en) | 2021-10-18 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Eukaryotic cells comprising adenovirus-associated virus polynucleotides |
| US20250019668A1 (en) | 2021-10-29 | 2025-01-16 | Ultragenyx Pharmaceutical Inc. | Engineered cell lines for increased production of recombinant adeno-associated virus (raav) |
| CN119137263A (zh) | 2022-03-07 | 2024-12-13 | 奥特吉尼克斯制药公司 | 改进的分批aav产生系统和方法 |
| WO2025078616A1 (en) * | 2023-10-12 | 2025-04-17 | Cevec Pharmaceuticals Gmbh | Cellular factors affecting recombinant aav production |
| WO2025226558A1 (en) | 2024-04-22 | 2025-10-30 | Ultragenyx Pharmaceutical Inc. | Multi-step filtration and clarification methods for recombinant adeno-associated virus purification |
| WO2026078664A1 (en) | 2024-10-10 | 2026-04-16 | Instituto De Biologia Experimental E Tecnológica (Ibet) | Transcription factor enhancing recombinant adeno-associated virus production, products, methods and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5387484A (en) | 1992-07-07 | 1995-02-07 | International Business Machines Corporation | Two-sided mask for patterning of materials with electromagnetic radiation |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| AU707866B2 (en) | 1994-12-06 | 1999-07-22 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
| US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| US5688676A (en) | 1995-06-07 | 1997-11-18 | Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| AU741605B2 (en) | 1996-12-18 | 2001-12-06 | Targeted Genetics Corporation | AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| JP2001514845A (ja) * | 1997-09-05 | 2001-09-18 | ターゲティッド ジェネティクス コーポレイション | 組換えａａｖベクターの高力価ヘルパーなし調製物を生成するための方法 |
| AU764130B2 (en) | 1998-10-27 | 2003-08-14 | Crucell Holland B.V. | Improved AAV vector production |
| DE19905501B4 (de) | 1999-02-10 | 2005-05-19 | MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie | Verfahren zur Herstellung eines rekombinanten Adeno-assoziierten Virus, geeignete Mittel hierzu sowie Verwendung zur Herstellung eines Arzneimittels |
| WO2004075861A2 (en) | 2003-02-26 | 2004-09-10 | Children's Hospital, Inc. | Recombinant adeno-associated virus production |
| WO2006125830A2 (en) * | 2005-05-27 | 2006-11-30 | Evotec Neurosciences Gmbh | Kcnn3 as diagnostic and therapeutic target for neurodegenerative diseases |
| EP2311967B1 (en) | 2005-10-20 | 2017-09-20 | UniQure IP B.V. | Improved AAV vectors produced in insect cells |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| KR20150133695A (ko) | 2013-02-05 | 2015-11-30 | 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 | 바이러스 제조를 위한 세포주 및 이의 사용 방법 |
| CN104592364B (zh) * | 2013-10-30 | 2018-05-01 | 北京大学 | 定点突变和定点修饰的腺相关病毒、其制备方法及应用 |
| GB201401707D0 (en) * | 2014-01-31 | 2014-03-19 | Sec Dep For Health The | Adeno-associated viral vectors |
| US20160319277A1 (en) | 2015-01-28 | 2016-11-03 | The Johns Hopkins University | METHODS OF IMPROVED PROTEIN PRODUCTION USING MIRNAs AND SIRNAs |
| PL3436593T3 (pl) | 2016-03-28 | 2023-03-27 | Ultragenyx Pharmaceutical Inc. | Sposoby inaktywacji termicznej adenowirusów |
| US20190290710A1 (en) | 2016-07-12 | 2019-09-26 | Dimension Therapeutics, Inc. | Use of glucocorticoid analogs to enhance recombinant adeno-associated virus yield |
| ES3012649T3 (en) | 2016-10-14 | 2025-04-09 | Ultragenyx Pharmaceutical Inc | Use of tonicifying agents to enhance recombinant adeno-associated virus yield |
| JP7142643B2 (ja) | 2017-03-22 | 2022-09-27 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | Ｈｄａｃ阻害剤またはｒｅｐタンパク質を伴う細胞培養方法 |
| US20200048641A1 (en) | 2017-03-22 | 2020-02-13 | Ultragenyx Pharmaceutical Inc. | Methods for enhancing yield of recombinant adeno-associated virus |
| JP7218303B2 (ja) | 2017-05-09 | 2023-02-06 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | トランスフェクション試薬を生成するための拡大可能な方法 |
| US20200340013A1 (en) | 2018-01-19 | 2020-10-29 | The University Of North Carolina At Chapel Hill | Methods and compositions for inhibition of innate immune response associated with aav transduction |
| WO2020219543A1 (en) | 2019-04-26 | 2020-10-29 | The Regents Of The University Of California | Cells for enhanced production of adeno-associated virus |
| US20250019668A1 (en) * | 2021-10-29 | 2025-01-16 | Ultragenyx Pharmaceutical Inc. | Engineered cell lines for increased production of recombinant adeno-associated virus (raav) |
-
2020
- 2020-04-09 AU AU2020270960A patent/AU2020270960B2/en active Active
- 2020-04-09 WO PCT/US2020/027489 patent/WO2020210507A1/en not_active Ceased
- 2020-04-09 KR KR1020217036581A patent/KR20210152514A/ko active Pending
- 2020-04-09 MX MX2021012489A patent/MX2021012489A/es unknown
- 2020-04-09 US US16/844,475 patent/US12018288B2/en active Active
- 2020-04-09 CN CN202080028310.8A patent/CN113966395B/zh active Active
- 2020-04-09 EP EP25183274.7A patent/EP4603579A3/en active Pending
- 2020-04-09 CA CA3136246A patent/CA3136246A1/en active Pending
- 2020-04-09 BR BR112021020391A patent/BR112021020391A2/pt unknown
- 2020-04-09 JP JP2021559793A patent/JP7560475B2/ja active Active
- 2020-04-09 EP EP20722185.4A patent/EP3953458A1/en active Pending
- 2020-04-09 PH PH1/2021/552577A patent/PH12021552577A1/en unknown
- 2020-04-09 SG SG11202110904PA patent/SG11202110904PA/en unknown
- 2020-04-10 TW TW109112259A patent/TWI859216B/zh active
-
2021
- 2021-10-07 IL IL287106A patent/IL287106A/en unknown
- 2021-10-14 CO CONC2021/0013699A patent/CO2021013699A2/es unknown
-
2024
- 2024-05-09 US US18/659,358 patent/US20240376440A1/en active Pending
- 2024-06-11 JP JP2024094278A patent/JP7706607B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7094323B2 (ja) | 最適化機能ＣＲＩＳＰＲ－Ｃａｓ系による配列操作のための系、方法および組成物 | |
| CN114634930B (zh) | 使用rna指导型内切核酸酶改善基因组工程特异性的组合物和方法 | |
| US11111506B2 (en) | Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides | |
| ES2735773T3 (es) | Acidos nucleicos manipulados dirigidos a ácidos nucleicos | |
| JP6914274B2 (ja) | Ｃｒｉｓｐｒｃｐｆ１の結晶構造 | |
| EP3350327B1 (en) | Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids | |
| AU2017268842B2 (en) | Peptides and nanoparticles for intracellular delivery of genome-editing molecules | |
| CN105121641B (zh) | Rna-引导的人类基因组工程化 | |
| JP2020537516A (ja) | 標的化された核酸編集のためのシステム、方法、及び組成物 | |
| WO2021067788A1 (en) | Crispr systems with engineered dual guide nucleic acids | |
| US20250257342A1 (en) | Peptides and nanoparticles for intracellular delivery of genome-editing molecules | |
| JP2024107295A5 (https=) | ||
| JP2022526646A (ja) | 操作された産生細胞株ならびにそれを作製および使用する方法 | |
| JPWO2020210507A5 (https=) | ||
| Garcia-Guerra et al. | Tissue-specific modulation of CRISPR activity by miRNA-sensing guide RNAs | |
| RU2021132765A (ru) | Линии сконструированных клеток-продуцентов и способы их получения и применения | |
| US20250257340A1 (en) | Guide nucleic acid identification and methods of use | |
| TH2101006399A (th) | เซลล์ไลน์ผู้ผลิตที่ผ่านการทำวิศวกรรม และวิธีการสร้างและการใช้สิ่งเดียวกันนี้ | |
| US20250354177A1 (en) | System and methods for duplicating target fragments | |
| JP2025514304A (ja) | 遺伝子治療法のための組織特異的遺伝子外セーフハーバーの同定 | |
| Ruwe et al. | Virus-induced genome editing in the parasitic plant Phtheirospermum japonicum | |
| HK40064529A (en) | Peptides and nanoparticles for intracellular delivery of genome-editing molecules | |
| EP4601650A2 (en) | Compositions and methods for targeting, editing, or modifying genes | |
| WO2018223843A1 (zh) | 用于dna编辑的系统及其应用 | |
| van Brabant Smith | Versatility of chemically synthesized guide RNAs for CRISPR-Cas9 genome editing |